EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Presence of anti‐modified protein antibodies in idiopathic pulmonary fibrosis

Dimitrios Kalafatis iD, Vijay Joshua, Monika Hansson, Linda Mathsson-Alm, Aase Hensvold, Magnus Sköld

Respirology · 2023

DOI: 10.1111/resp.14543 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Respirology, 2023. Verfasst von Dimitrios Kalafatis und 5 weiteren Autor:innen. Beteiligte Einrichtung: Respiratory Medicine Unit, Department of Medicine Solna and Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Idiopathic Pulmonary Fibrosis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Boehringer Ingelheim, Karolinska Institutet, Roche.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objective Studies of autoimmunity and anti‐citrullinated protein antibodies (ACPA) in idiopathic pulmonary fibrosis (IPF) have been confined to investigations of anti‐cyclic citrullinated peptide (anti‐CCP) antibodies which utilize synthetic peptides as surrogate markers for in vivo citrullinated antigens. We studied immune activation by analysing the prevalence of in vivo anti‐modified protein antibodies (AMPA) in IPF.

Methods

We included patients with incident and prevalent IPF ( N = 120), sex and smoking‐matched healthy controls (HC) ( N = 120) and patients with RA ( N = 104). Serum (median time: 11 months [Q1–Q3: 1–28 months] from diagnosis) was analysed for presence of antibodies towards native and posttranslational modified (citrullinated [Cit, N = 25]; acetylated [Acet, N = 4] and homocitrullinated [Carb, N = 1]) peptides derived from tenascin (TNC, N = 9), fibrinogen (Fib, N = 11), filaggrin (Fil, N = 5), histone ( N = 8), cathelicidin (LL37, N = 4) and vimentin ( N = 5) using a custom‐made peptide microarray.

Results

AMPA were more frequent and in increased levels in IPF than in HC (44% vs. 27%, p < 0.01), but less than in RA (44% vs. 79%, p < 0.01). We specifically observed AMPA in IPF towards certain citrullinated, acetylated and carbamylated peptides versus HC: tenascin (Cit (2033) ‐TNC 2025–2040 ; Cit (2197) ‐TNC 2177–2200 ; Cit (2198) ‐TNC 2177–2200 ) , fibrinogen (Cit (38,42) ‐Fibα 36–50 ; Cit (72) ‐Fibβ 60–74 ) and filaggrin (Acet‐Fil 307–324 , Carb‐Fil 307–324 ). No differences in survival ( p = 0.13) or disease progression ( p = 0.19) between individuals with or without AMPA was observed in IPF. However, patients with incident IPF had better survival if AMPA were present ( p = 0.009).

Conclusion

A significant proportion of IPF patients present with specific AMPA in serum. Our results suggest autoimmunity as a possible characteristic for a subgroup of IPF that may affect disease outcome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidIdiopathic Pulmonary FibrosisHumansAutoantibodiesFilaggrin ProteinsTenascinalpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic AcidPeptides, CyclicPeptidesFibrinogen

Stichwörter der Autor:innen

anti-citrullinated peptideanti-modified protein antibodiesidiopathic pulmonary fibrosisprognosisrheumatoid arthritis

Substanzen

AutoantibodiesFilaggrin ProteinsTenascinalpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic AcidPeptides, CyclicPeptidesFibrinogen

Autor:innen und Institutionen

  • Respiratory Medicine Unit, Department of Medicine Solna and Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Division of Rheumatology, Department of Medicine Solna and Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Thermo Fisher Scientific, Uppsala, Sweden.
  • Center for Rheumatology, Academic Specialist Center, Stockholm Health Region, Stockholm, Sweden.
  • Department of Respiratory Medicine and Allergy, Karolinska University Hospital, Stockholm, Sweden.

ORCID-Profile: Dimitrios Kalafatis

Förderung

  • Boehringer Ingelheim
  • Karolinska Institutet
  • Roche

Zitieren

APA

Kalafatis, D., Joshua, V., Hansson, M., Mathsson-Alm, L., Hensvold, A., & Sköld, M. (2023). Presence of anti‐modified protein antibodies in idiopathic pulmonary fibrosis. Respirology. https://doi.org/10.1111/resp.14543

Vancouver

Kalafatis D, Joshua V, Hansson M, Mathsson-Alm L, Hensvold A, Sköld M. Presence of anti‐modified protein antibodies in idiopathic pulmonary fibrosis. Respirology. 2023. doi:10.1111/resp.14543

BibTeX
@article{Kalafatis2023,
  author = {Kalafatis, Dimitrios and Joshua, Vijay and Hansson, Monika and Mathsson-Alm, Linda and Hensvold, Aase and Sköld, Magnus},
  title = {Presence of anti‐modified protein antibodies in idiopathic pulmonary fibrosis},
  journal = {Respirology},
  year = {2023},
  doi = {10.1111/resp.14543}
}
Kostenlos starten →